Member Info for HereforHemo

That would mean the SP well above £4 and another £700,000 in the bank for Hemogenyx, nothing wrong with that imo.

Imagine hearing in little over a week that the very first patient treated with HG-CT-1 has come through the initial 28 days without incident and is now at home.

Imagine hearing the hospital and Hemogenyx are preparing patient two for the infusion of HG-CT-1 the following week.

Imagine hearing that Hemogenyx are now funded until June (albeit painfully so) which will be enough to treat the first four patients.

Imagine if as I expect the data from these four patients is positive in both safety and efficacy.

Imagine how much HG-CT-1 would then be worth to either VC's or major pharmaceutical companies.

Imagine either of the above taking a stake and investing millions or tens of millions into Hemogenyx or HG-CT-1 to progress it through the various stages of the trials.

Now Imagine what the Hemogenyx Mcap and share price would be with a fully funded trial and a therapy with the potential to generate hundreds of millions of dollars in revenue that you not only designed but manufacture yourself.

Would it still be £6m? £20m? £100m? More?

Personally u have no idea what it could be but one thing I know for sure, it's going to be worth a damm sight more than £6m. Each and every milestone ticked off will add value and I for one am confident the next investment into Hemogenyx will be substantial and it'll come in Q2.

Bicker amongst yourselves if you want. I'll just wait calm confident and patient.

Micky ignore the muppets, just read the secondary objectives as outlined in the RNS.

Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML.

Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses.

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML.

In short, we'll know whether this therapy works soon enough.

Finance from the United States or China? Or maybe the EU, who are making moves in Africa...

https://www.euronews.com/my-europe/2025/03/13/eu-targets-africas-mineral-wealth-and-green-energy-in-new-partnership

Micky as I understand it after the share conversion Vlad and his wife were left owning 291,000 shares, so the drop in the share price had a major impact on them. As for Vlad being wealthy, I don't know the tax rates in America but up to 2023 he earned around 200k a year, but again I have no idea of his outgoings. In 2024 I think his salary increased to £400k but again I would suggest nobody knows his outgoings and whether he had a spare £1m to loan the company rather than do the recent raises.

Unfortunately it is what it is. Positive results are what we need now, and nobody needs them more than Vlad.

Let's wait a week or so. Everything will be clearer to us all.

Micky whilst I understand your frustration (I assure you I'm down a lot more than you on Hemogenyx) it's not that nobody is interested. It's that nobody is interested UNTIL it's proven its effective.

Once we start getting the data, within days for the first patient, and if it's positive then it's simply impossible that Hemogenyx will still have a Mcap of £6.5m. The product alone will be worth tens if not hundreds of millions of dollars. That's an absolute fact.

The risk here as its always been is does it work. We can guess its safe after not hearing anything negative for around 3 weeks so now it's down to whether it's effective. If it is, everyone's losses will disappear!

Just my thoughts.

Moorscloud/DCT the irony here is that Vlad kept 100% ownership of everything (as he tweeted many years ago) that he believed selling anything before it was proven in the clinic was a dereliction of duty to shareholders. Now with extremely poor financing decisions its not only shareholders who have suffered with dilution but Vlad and his wife as well.

As I have informed Vlad, we're now at a critical juncture. There is no headroom to place again at these levels. He simply has to sell or licence CAR-T. Thankfully he is funded to get results from 3 or 4 patients that allow him to demonstrate its both safe and has efficacy. If results are favorable will he get a good deal/price for it? I believe he will, on the basis multiple companies will want it, if the results are as good as we think they are.

I know he's now getting the relevant data from the hospital and the fact he's praising his team in parallel gives me cause for optimism. Hence I remain calm and patient.

Whilst painful at the moment I still maintain that it's the clinical data that Hemogenyx are now receiving that will define our investment.

With funding secured to treat the first 3/4 patients I'm also hopeful that with little headroom left that'll be the last of the discounted offers, and the next monies raised will be from pharmaceutical companies buying directly into CAR-T.

Not long to wait to find out the results from patient one and if, as i expect they're positive from both safety and efficacy then we'll rapidly see a different story on the SP.

Just my opinion but I remain calm, positive and patient.

Ricky 550k bought to 80k sold.

Yet another ambiguous RNS from Hemo.

'the initial patient was infused with HG-CT-1 in February 2024 and, subject to a satisfactory outcome, a second patient will be recruited and treated as quickly as practical'

Followed by

'We are very happy with the progress of our clinical trial and this allows us to take a significant step forward'

So, if they're happy with their progress and have secured funding to inject further patients why would they include the first paragraph I've eluded to?

Most of us believe Vlad has real-time analysis from patient one and believe the results from patient one, to date, are looking very promising.

So Vlad, if you're happy with the progress of the trial so far to the degree you're looking to use these funds to treat additional patients, do a bloody interview and tell people!

Saint that's my point. The only way it will get to £3 and above to allow them to sell into any rise is on successful results of the first patient, which will be known in a matter of days.

The only comfort i take today is for any institution to invest over 700k so close to results of the first patient, its either a massive gamble by them or they know something we dont from the real-time data Vlad has collated from the first two weeks.

At least we're funded for a few patients now, hopefully through to a major getting involved. Now we hope for excellent results. Patients lives are at stake. Our investments are at stake and Vlads decade of work building Hemogenyx the company is at stake. Pointless being angry and emotional imo. This was always a binary play. It still is.

CEO, Dr Vladislav Sandler, said: "We are very pleased with the progress of the clinical trials for our lead product, HG-CT-1.

"We are greatly encouraged by the confidence shown by the backing of the institution and are grateful for their support in advancing our mission to bring innovative treatments to patients with acute myeloid leukemia.

"This investment enables us to take a significant step forward with our HG-CT-1 program, moving further with clinical trials and bringing us closer to providing a new therapeutic option for patients facing this aggressive disease."

No boredom for me. I have one eye on getting the results of patient one, who day by day gets closer to the 28 days mandated by the FDA, 9 trading days left after today.

The other eye is firmly fixed on the end of Q2. Four patients should have been treated, the trial moves to one patient every two weeks and more importantly that's when I expect a major to step in and finance Hemogenyx with big money.

We have pediatric AML and 24 hour manufacturing to look forward to as well. So no boredom, just waiting patiently for value to arrive.

Vlad said in his recent interview Hemo CAR-T had at least the same efficacy as the handful of approved therapies but being a 3rd generation product was safer.

Another 10 trading days and we should hear about the progress of patient one, and preparations/infusion of patient two. Things appear to be going extremely well and once confirmed i think we jump to 10p+.

Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are thrilled to take this critical step in advancing the development of HG-CT-1. This milestone not only validates our years of research and development, but also brings us closer to providing a transformative treatment for patients suffering from relapsed or refractory AML.

Things can change quickly ...

Written by Nathan Reiff, MarketBeat Contributor for MarketBeat->

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA.

In these latter cases, biotech stocks can see incredible rallies outpacing most other spaces in the market. A recent example is Bright Minds Biosciences Inc. (NASDAQ: DRUG), whose shares jumped from about $2.50 each to nearly $39 a piece in the span of two days in October 2024 after releasing data suggesting one of its proprietary compounds demonstrated similar efficacy to morphine in certain pain models.

Me, I just look at the Prevail Investment Fund and their two investments:

Prevail Partners, an Investment Fund has agreed to invest a total of $350,000 (£269,000) in the company through a subscription for ordinary shares in the company for a price of US$0.075 per share (approximately 5.6p. The subscription price represents a premium of approximately 275% to the company's closing share price.

Prevail Partners, an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000). The subscription price represents a premium of approximately 240% to the Company's closing share price.

And they know the science better than all of us.

Whoever took part to buy in at £3.40 would be an imbecile to sell at this level, regardless of having 50k warrants at £5.00. Even the existing holders would be scraping the barrel selling shares they've held I'm advance of being allocated new ones, in my opinion anyway.

Thank god patient one is through the critical period and two weeks away from the 28 days mandated by the FDA. We can get initial results out and patient two can be injected, then focus on the trial rather than daily squabbling as to who's sold and who hasn't, which in the scheme of things is bloody irrelevant.

I for one believe Vlad DOES know exacly how the trial is going due to the real time analytical data the Prevail system offers, both for safety and efficacy which can also be directly compared to previous studies and even used to assist in choosing the right candidates to participate.

https://prevailinfoworks.com/wp-content/uploads/2024/01/Analyze-Data-in-Live-Studies-Without-Unblinding-or-Spending-Alpha-Henry.mp4

Socialist it wasn't AI generated I just took an extract from one of the CAR-T reports I was reading. Unfortunately I've looked at so many I can't remember which one I took it from..

If you just Google 'CAR-T market' you'll find lots of informative reports.

Micky. What happens is that the hospital prepare the patient and take the patients blood. That is then shipped to Hemogenyx. Hemogenyx then take that blood and manufacture the CAR-T cells that kill the cancer, freeze it and then send it back to the hospital. That is then injected back into the patient so the CAR-T can begin targeting and killing the cancer cells. It's after this infusion that the 28 days start which is why it's exciting they're passed the first 14 days without a negative reaction from the patient.